RNAC Stock Forecast & Price Target

Cartesian Therapeutics has demonstrated a positive trajectory in clinical outcomes, highlighted by recent Phase 2b data showcasing sustained, clinically meaningful improvements with an average reduction of 4.8 in MG-ADL at 12-month dosing intervals. The safety profile of Descartes-08 remains robust, with no significant adverse events reported, which suggests a favorable risk-benefit balance for patients, potentially leading to increased market adoption. Furthermore, the differentiated mechanism of action, including significant reductions in multiple interferon-linked cytokines, positions Descartes-08 favorably compared to existing therapies, allowing for broader therapeutic applications in various autoimmune conditions.

Cartesian Therapeutics Inc has experienced a notable decline in cash reserves, from $162.1 million in Q2 2025 to $145.1 million in Q3 2025, primarily due to increased operating expenses associated with its Phase 3 Myasthenia Gravis (MG) program, although management maintains that current cash will sustain operations through mid-2027. The company’s market capitalization is below $200 million, leading to an effective enterprise value of around $50 million, which appears low for a firm with a Special Protocol Assessment-backed Phase 3 program despite previous Phase 2 data supporting its safety and efficacy. Investor sentiment remains cautious, with little to no value attributed to the Descartes-08 program for MG and concerns about the high treatment burden and unmet needs in the autoimmune disease landscape limiting growth potential.